Blog
RSS FeedPosted by Michael Wonder on 11 Jun 2016
CADTH calls for patient input on submission from Teva for Fentora (fentanyl citrate)
10 June 2016 - CADTH calls for patient input on a submission from Teva Pharmaceuticals for Fentora (fentanyl citrate). ...
Posted by Michael Wonder on 10 Jun 2016
PHARMAC to seek further advice on azithromycin funding proposal
10 June 2016 - PHARMAC received a number of high-quality, well considered responses to the proposal to amend the funding restrictions ...
Posted by Michael Wonder on 09 Jun 2016
Cancer drug 'a long time coming'
10 June 2016 - PHARMAC has been accused of leaving melanoma patients in suspense by not telling them earlier when their ...
Posted by Michael Wonder on 09 Jun 2016
NICE publishes second appraisal consultation for Nucala (mepolizumab)
9 June 2016 - NICE has published a second appraisal consultation for GSK's Nucala (mepolizumab). ...
Posted by Michael Wonder on 09 Jun 2016
Government announces new drug funding, including for advanced melanoma
9 June 2016 - Medicine to treat six diseases, including for advanced melanoma, will be available to New Zealanders. ...
Posted by Michael Wonder on 09 Jun 2016
NICE’s Eylea guideline ‘out of touch with clinical practice’
9 June 2016 - Bayer says it is disappointed that NICE is supporting NHS use of anti-VEGF therapy Eylea to treat ...
Posted by Michael Wonder on 09 Jun 2016
Canada's health technology assessment agency gives positive recommendation for Opdivo to treat non-small cell lung cancer
8 June 2016 - Opdivo is the first immuno-oncology therapy for lung cancer in Canada to use the body’s own immune ...
Posted by Michael Wonder on 09 Jun 2016
Health sector feedback helps make the most of Government funding boost
9 June 2016 - PHARMAC is today announcing funding of six new treatments across important areas of health, including major advancements ...
Posted by Michael Wonder on 08 Jun 2016
CADTH calls for patient input on submissions from Daiichi Sankyo for edoxaban tosylate
8 June 2016 - CADTH has received notice of pending submissions from Daiichi Sankyo for edoxaban tosylate. ...
Posted by Michael Wonder on 08 Jun 2016
The Cancer Drugs Fund
8 June 2016 - Over the past five years thousands of patients in England have been given access to new but ...
Posted by Michael Wonder on 08 Jun 2016
New fund set up to support research into medicines usage in NZ
8 June 2016 - Why do people not take all the medicine prescribed for them? Why are there differences in the ...
Posted by Michael Wonder on 07 Jun 2016
Registration and reimbursement of new cancer medicines in Australia
7 June 2016 - This letter to the Editor of Value in Health Regional Issues for Asia responds to a ...
Posted by Michael Wonder on 06 Jun 2016
Health system cares for big insurers, big pharma
7 June 2016 - Although there are some differences between the major parties on health policy, all sides embrace the concept ...
Posted by Michael Wonder on 06 Jun 2016
Biosimilar Awareness Initiative Reference Group communiqués
6 June 2016 - The communiqués from the meetings of the Biosimilar Awareness Initiative Reference Group are now available. ...
Posted by Michael Wonder on 04 Jun 2016
CADTH issues final recommendation for nivolumab (Opdivo) for use in patients with non-small-cell lung cancer
3 June 2016 - Final recommendation is conditional on cost-effectivness being improved to an acceptable level. ...